Tenderwize
Retour à la recherche

Open house discount agreements for Rilpivirin depot injection suspension, ATC J05AG05

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 583 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rilpivirin in der Darreichungsform Depot-Injektionssuspension, ATC J05AG05

60/100

Score d'opportunité

PromisingLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

No estimated contract value or maximum framework amount is provided. It is unclear what volume of business these discou...

The open-house agreements may automatically terminate if a national or regional discount contract for the same product...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Non-exclusive discount agreements for the pharmaceutical product Rilpivirin (ATC J05AG05) in depot injection suspension form.
  • Contracts are offered to all eligible pharmaceutical companies without competition.
Afficher le résumé complet

This is an open-house model (not a standard procurement procedure) for non-exclusive discount agreements for the pharmaceutical product Rilpivirin in depot injection suspension form (ATC J05AG05). The buyer, AOK Bayern, offers identical, non-negotiable contracts to all interested pharmaceutical companies that meet the eligibility criteria. The early possible start date is 01.06.2026, all contracts end 31.05.2028. Contract conclusion is possible anytime until 03.04.2028. Termination is possible with one month's notice. There is no competition or award selection; any eligible company can join. The estimated value is not provided.

Risques

No estimated contract value or maximum framework amount is provided. It is unclear what volume of business these discou...

The open-house agreements may automatically terminate if a national or regional discount contract for the same product...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contracting partners.
  • Eligibility is proven by a signed self-declaration of reliability (downloadable from the procurement documents).

Administrative

  • Submission must include the signed contract, the signed annex "Determination of the contract medicines", and the signed self-declaration.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house discount agreements for Rilpivirin depot injection suspension, ATC J05AG05

Non-exclusive discount agreements for the active substance Rilpivirin in depot injection suspension form. Contracts are identical for all participants. The contract period is from 01.06.2026 to 31.05.2028. Submission deadlines are rolling: to get a contract start on the next month's first day, complete documents must be submitted by the 3rd of the previous month.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 03, 2028

Détails de la procédure

Date de publication
14 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
255478-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30